ZY - ZY STOCK NEWS

Zymergen Inc. will participate in the 42nd Annual Cowen Virtual Healthcare Conference on March 8, 2022, at 2:50 p.m. ET. The presentation can be accessed live and archived on the company's website. Zymergen specializes in designing and producing molecules, microbes, and materials aimed at various markets, highlighting its commitment to partnering with nature for innovative product solutions.

Zymergen (ZY) announced the launch of its new Automation business aimed at enhancing lab efficiency and throughput. The patented automation technology will address the industry's technology gap, reducing workloads significantly. Additionally, Zymergen is refining its product portfolio, focusing on high-value microbes and materials. Key advancements include a nitrogen fixation program that has halved onboarding time and promising results from its mRNA enzyme portfolio. The company believes these strategic initiatives position it for future growth and product opportunities.

Zymergen (ZY) has launched a new drug discovery business utilizing its proprietary synthetic biology platform and extensive metagenomics database. This database, which rivals all publicly available datasets, offers access to a vast range of novel natural products from uncultured microbes, potentially enhancing drug discovery for oncology targets. The acquisition of Lodo Therapeutics bolsters Zymergen's capabilities in metagenomics and drug development. The innovative approach combines next-gen sequencing and machine learning to accelerate therapeutic discovery, aiming to deliver superior treatments for patients.

Zymergen Inc. announced its participation in the 40th Annual J.P. Morgan Virtual Healthcare Conference, taking place on January 10th, 2022, at 2:15 p.m. ET. The conference presentation will be accessible via a live and archived webcast on the company's website. Zymergen focuses on designing and producing innovative molecules, microbes, and materials, aligning its mission with sustainability and improved product offerings.

Zymergen has reported preliminary financial results for Q3 2021, revealing total revenues of $4.1 million from R&D service agreements. Operating expenses reached $99.3 million, including $21.2 million in restructuring charges. The net loss for the quarter was $98.2 million. The company is refocusing its portfolio, discontinuing several programs, and laying off approximately 220 employees to reduce cash burn rate. As of September 30, 2021, cash and equivalents stood at $496.2 million. Further details will be disclosed in their upcoming Form 10-Q.

Zymergen Inc. (Nasdaq: ZY) will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call hosted by management will take place at 1:30 p.m. PT (4:30 p.m. ET) to discuss results, business developments, and future outlook. Investors can access a webcast of the call on Zymergen's investor relations website. Zymergen specializes in biofacturing, using a blend of biology, chemistry, software, and automation to create innovative bio-based products.

Zymergen Inc. (Nasdaq: ZY) announces the appointment of Lincoln Germain as Chief Commercial Officer and Subodh Deshmukh as Chief Development Officer. Germain, with over 25 years of experience, will focus on rebuilding the commercial team and enhancing sales processes. Deshmukh brings over 20 years of development expertise, previously leading product development at Sandoz. The leadership changes aim to bolster Zymergen's operational capabilities and drive growth in bio-based product development, positioning the company for strategic advancements.

Zymergen has announced a significant business update, revealing that it no longer expects product revenue in 2021 and anticipates only immaterial revenue in 2022. Technical issues with key customer implementations of its product, Hyaline, have caused delays in commercial ramp-up. Jay Flatley has been appointed as Acting CEO following Josh Hoffman's departure. Zymergen reported Q2 estimates of $5-6 million in revenue, with operating expenses projected at $100-105 million. The company plans to align expenses with revised revenue expectations as it reassesses its target markets.

Zymergen, a leader in biofacturing, will participate in the Goldman Sachs Annual Global Healthcare Virtual Conference on June 9th at 5:30 PM ET. The presentation can be accessed live and on-demand via the company's website. Zymergen specializes in using biology, chemistry, software, and automation to create bio-based products across various industries. This participation marks an important event for investors and stakeholders looking to understand the company's innovative approaches and market contributions.